The antiarrhythmic activity of amino acid-containing derivatives of 1,4-naphthoquinone

封面

如何引用文章

全文:

详细

In recent times, the issue of cardiac arrhythmia disturbances has garnered increasing attention from researchers. Pharmacotherapy continues to be the primary method for treating rhythm disturbances; however, its effectiveness is often limited due to the common side effects associated with many antiarrhythmic drugs, among which negative inotropic action plays a significant role. One direction in the development of antiarrhythmic agents involves the targeted search for new drugs among agents with metabolic effects. The aim of this study was to investigate the antiarrhythmic activity using models of occlusion and reperfusion arrhythmias in cats, aconitine arrhythmias in rats, and calcium chloride ventricular fibrillation in rats of five original amino acid-containing derivatives of 1,4-naphthoquinone, synthesized at the Lviv Polytechnic Institute under the guidance of Ph.D. A.P. Kartoflitska. The conducted research indicated that the studied compounds exhibit antiarrhythmic effects. The enhancement of the antiarrhythmic activity occurred primarily in those arrhythmia models where metabolic disorders play a significant role in the pathogenesis.

作者简介

Svetlana Napalkova

Saint Petersburg State Chemical and Pharmaceutical University

编辑信件的主要联系方式.
Email: svetlana.napalkova@pharminnotech.com
ORCID iD: 0000-0002-9216-8673
SPIN 代码: 7311-2841

D.Sc. in Biology, Professor, Professor at the Department of Pharmacology and Clinical Pharmacology

俄罗斯联邦, Saint Petersburg

Olga Buyuklinskaya

Saint Petersburg State Chemical and Pharmaceutical University

Email: olga.buyklinskaya@pharminnotech.com
ORCID iD: 0000-0002-4453-1079
SPIN 代码: 9691-6490

Dr.Med.Sci,  Professor at the Department of Pharmacology and Clinical Pharmacology

俄罗斯联邦, Saint Petersburg

参考

  1. Miller O.N., Syrov A.V., Doshchitsin V.L., Pavlova T.V., Tarasov A.V. Clinical guidelines and expert opinion on the use of antiarrhythmic drugs in actual practice // Consilium Medicum. - 2019. - Vol. 21. - N. 5. - P. 43-50. doi: 10.26442/20751753.2019.5.190328. (In Russ).
  2. Jones, B., & Burnand, C. Antiarrhythmic drugs. Anaesthesia & Intensive Care Medicine, 2021; 22(5): 319-323.
  3. Nanasi P.P., Pueyo E., Virag L. Perspectives of Antiarrhythmic Drug Therapy: Disappointing Past, Current Efforts, and Faint Hopes. Frontiers in Pharmacology, 2020; 11: 1116.
  4. A.c. SSSR 1690339. N-(3-khloro-1,4-naftokhinonil-2)-2-D,L-asparaginovaya kislota, proyavlyayushchaya kardiostimuliruyushchie svoistva / A.P. Kartoflitskaya, V.T. Kolesnikov, V.S. Zybin, N.M. Mitrokhin, Yu.V. Burov, N.S. Diogenova, A.A. Guzova; zayavl. 30.03.1990, opubl. 20.09.1999; Byul. № 42. (In Russ).
  5. Marakhovsky Yu.Kh. Clinical evaluation of amino acids as drugs: separate systematized ana-lytical sketches. Recipe. 2012;4(84):124-140. (In Russ).
  6. Shenasa, M., Shenasa, MA., Smith, M. (2020). Class I Antiarrhythmic Drugs: Na+ Channel Blockers. In: Martínez-Rubio, A., Tamargo, J., Dan, G . (eds) Antiarrhythmic Drugs. Current Cardiovascular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-34893-9_2

版权所有 © Eco-Vector, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##